(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Savvy Locks for Lofts - 2Raw oysters linked to ongoing salmonella outbreak infecting 64 across 22 states: CDC
- 3Tech for Efficiency: Applications and Apparatuses to Accomplish More
- 4Architect Frank Gehry has died: See his most iconic buildings
- 5Good ways to respond if your kid brings home less-than-ideal grades
- NASA troubleshoots Artemis II toilet problem in otherwise smooth flight
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- Most loved Solace Food: What's Your Definitive Comfortable Dinner?
- More Than 110 New Species Discovered In Deep Waters Off Australia
- China resumes flights to North Korea after a six-year pause
- Regeneron's experimental therapy combo effective in untreated cancer patients
- Audits of 6 American Busssiness Class Flights
- What to know about MIT professor Nuno Loureiro and the investigation into his shooting
- How many ships have been attacked in the Gulf since start of Iran war?
